Rhumbline Advisers Humanigen, Inc Transaction History

Rhumbline Advisers

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$1.76 - $3.33 $81,595 - $154,382	-46,361 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$1.81 - $3.97 $2,450 - $5,375	1,354 Added 3.01%	46,361 $140,000
Q4 2021 Feb 10, 2022	SELL	$3.66 - $8.22 $2,913 - $6,543	-796 Reduced 1.74%	45,007 $167,000
Q3 2021 Nov 12, 2021	BUY	$5.93 - $17.83 $12,707 - $38,209	2,143 Added 4.91%	45,803 $272,000
Q2 2021 Aug 05, 2021	BUY	$13.54 - $22.74 $591,156 - $992,828	43,660 New	43,660 $759,000

558K

Ticker HGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,661,000
Description
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.